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ABSTRACT
CONTEXT AND OBJECTIVE: Around 16% to 20% of women with breast cancer have advanced, metastasized breast cancer. At this stage, the disease is 
treatable, but not curable. The objective here was to assess the effectiveness of lapatinib for treating patients with advanced or metastasized breast 
cancer. 
DESIGN AND SETTING: Systematic review of the literature, developed at Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São 
Paulo (Unifesp). 
METHOD: Systematic review with searches in virtual databases (PubMed, Lilacs [Literatura Latino-Americana e do Caribe em Ciências da Saúde], 
Cochrane Library, Scirus and Web of Science) and manual search. 
RESULTS: Only one clinical trial that met the selection criteria was found. This study showed that lapatinib in association with capecitabine reduced the 
risk of cancer progression by 51% (95% confidence interval, CI: 0.34-0.71; P < 0.001), compared with capecitabine alone, without any increase in severe 
adverse effects. 
CONCLUSION: The combination of lapatinib plus capecitabine was more effective than capecitabine alone for reducing the risk of cancer progression. 
Further randomized clinical trials need to be carried out with the aim of assessing the effectiveness of lapatinib as monotherapy or in association for 
first-line or second-line treatment of advanced breast cancer. 
RESUMO 
CONTEXTO E OBJETIVO: Aproximadamente 16% a 20% das mulheres com câncer de mama têm doença avançada com metástases. Neste estágio, 
a doença é tratável, porém incurável. O objetivo foi avaliar a efetividade do lapatinib no tratamento de pacientes com câncer de mama avançado ou 
metastático. 
TIPO DE ESTUDO E LOCAL: Revisão sistemática da literatura desenvolvida no Centro Paulista de Economia da Saúde (CPES), Universidade Federal de 
São Paulo (Unifesp). 
MÉTODO: Revisão sistemática com busca em bases de dados virtuais (PubMed, Lilacs [Literatura Latino-Americana e do Caribe em Ciências da Saúde], 
Cochrane Library, Scirus and  Web of Science) e busca manual.
RESULTADOS: Foi encontrado apenas um ensaio clínico que preencheu os critérios de seleção. Este estudo mostrou que o lapatinib em associação com 
a capecitabina reduziu em 51% o risco de progressão da doença (intervalo de confiança, IC 95%: 0,34-0,71; P < 0,001) quando comparado com a 
capecitabina isolada, sem aumento de efeitos adversos graves. 
CONCLUSÃO: A combinação de lapatinib e capecitabina foi mais efetiva do que a capecitabina isolada na redução do risco de progressão da doença. 
Ensaios clínicos aleatórios devem ser realizados com o objetivo de avaliar a efetividade do lapatinib como monoterapia ou em associação no tratamento 
primário ou secundário do câncer de mama avançado.
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INTRODUCTION
Breast cancer is the most common type of cancer found in women 
and is the main cause of cancer deaths among women.1 In 2000, more 
than one million new cases of breast cancer were reported, and approxi-
mately 373,000 deaths worldwide were attributed to this.1
While many cases of breast cancer in the early stages are successfully 
treated, it is considered incurable when there is recurrence of the disease 
with metastasis. Nevertheless, such situations are treatable.2
Advanced or metastasized breast cancer is defined as a clinical stage 
that corresponds to phases III and IV of the cancer, based on the tumor 
itself, lymph node involvement and metastases.3
Approximately 16% to 20% of women with breast cancer have ad-
vanced, metastasized breast cancer, and 50% of early-stage breast cancer 
ultimately develops to metastasized breast cancer.4 Some women with 
metastasized breast cancer live for many years, but the average survival 
upon diagnosis ranges from 18 to 24 months.3,5 Women with advanced 
or metastasized breast cancer that overexpresses epidermal growth factor 
receptors (EGFR) have a worse prognosis, with a high risk of recurrence 
after the primary treatment and a 50% reduction in mean survival.4-6
The treatment objective in cases of advanced or metastasized breast 
cancer is to control the symptoms and prolong life, given that such 
cases are considered incurable and that first-line surgery will have been 
ineffective.3-7 Although there is no evidence from randomized stud-
ies comparing chemotherapy with observation alone, among women 
with this type of breast cancer, it is widely accepted that these patients 
should receive some type of systematic treatment at some point dur-
ing the illness.8
In advanced cases, the therapies usually include prescription of an-
thracycline or a combination of cyclophosphamide, methotrexate and 
fluorouracil.9,10 The guidelines published by the National Institute for 
Health and Clinical Excellence (NICE) also include capecitabine, vi-
norelbine, docetaxel, paclitaxel, gemcitabine and trastuzumab.4,11-14
Considering that women with breast cancer with overexpression of 
EGFR are at greater risk of cancer progression, therapeutic strategies 
have been developed to block the activity of these receptors and to im-
prove the response to treatment.15,16
The EGFR family includes four subtypes: HER-1 (human epi-
dermal receptor), HER-2, HER-3 and HER-4.17-19 Overexpression of 
HER-1 occurs in approximately 27%-30% of breast cancer cases, while 
overexpression of HER-2 is recorded in 20%-25% of the 1.5 million 
new breast cancer cases diagnosed annually worldwide.17,18
These receptors do not stay put in a given spot on the cell mem-
brane, and the extracellular domains of pairs of receptors attach to each 
other via a connection that forms a dimer. These dimers may be ho-
modimers (i.e. two identical receptors, such as HER-1 and HER-1, etc.) 
or heterodimers (i.e. different receptors, such as HER-1 and HER-2, 
etc.).17-21 After dimerization, the intracellular tyrosine kinase domain is 
activated, thus stimulating cell proliferation.17
Lapatinib (GW572016/Tykerb; GlaxoSmithKline, Research Trian-
gle Park, North Carolina, United States) is an oral inhibitor of HER-1 
and HER-2 receptors that attaches to the intracellular tyrosine kinase 
domain, thereby blocking the growth of tumor cells.17,22 It presents 
some theoretical advantages over monoclonal antibodies that block the 
intracellular domain of the HER-2 receptor (e.g. trastuzumab, Hercep-
tin; Genentech, Inc., South San Francisco, California, United States).6
Inhibition of a single receptor subtype cannot be as effective as dou-
ble inhibition of the heterodimers containing HER-1 and HER-2.23 
Moreover, there are truncated receptors that do not have extracellular 
domains and that are not recognized by the antibodies that connect to 
this domain. In fact, a truncated form of HER-2 known as p95 that 
has much more tyrosine kinase activity than other forms of HER-2 has 
been documented.6 
Lapatinib has been effective in inhibiting p95HER-2 phosphoryla-
tion in BT474 cells and in tumor xenografts. On the other hand, tras-
tuzumab does not bind to or inhibit the p95HER-2 receptor, which 
suggests that resistance to trastuzumab can be measured through the 
overexpression of p95HER-2 receptors during cancer progression.24 
Overexpression of p95HER-2 receptors has also been observed as an 
independent prognostic factor for breast cancer cases, thus defining a 
group of patients with increased expression of HER-2 that demonstrates 
a shorter cancer-free survival period.25 In practice, in cases of metastasis, 
resistance to trastuzumab occasionally develops, in addition to recur-
rence after adjuvant therapy.26-30
Given the theoretical benefits of lapatinib, taking into account the 
prevalence of this type of cancer and the difficulty in managing it, a sys-
tematic review is necessary in order to map out the evidence available, 
prove the effectiveness of this medication and, thus, provide support for 
its use in treating advanced or metastasized breast cancer. 
OBJECTIVE
To assess the effectiveness of lapatinib as monotherapy or in associa-
tion with another drug during first-line or second-line treatment of pa-
tients with advanced or metastasized breast cancer. 
MATERIAL AND METHODS
1. Search strategy
A systematic review of the literature was conducted from the fol-
lowing sources: a) virtual search: Cochrane Library, PubMed, Embase, 
Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde), 
Web of Science and Scirus; b) manual search: search of the references 
listed in articles and congress abstracts, contacts with authors and con-
tacts with the pharmaceutical industry. The search strategy used for each 
virtual database is available in Table 1.
2. Study selection criteria
The criteria for study selection were that they should be random-
ized clinical trials assessing the effectiveness of lapatinib as monotherapy 
or in association with another drug, compared with placebo or anoth-
er intervention or treatment for women with advanced or metastasized 
breast cancer, as a first-line or second-line treatment. 
All abstracts from the 689 articles that were found were evaluated 
to select the likely clinical studies of interest. When in doubt, the article 
was evaluated in its entirety.
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3. Assessment of study methodological quality
The following evaluation scales were used: a) Jadad, ranging from 
0 to 5, in which higher ratings signified better methodological quality 
of implementation of the study; and b) the Cochrane Collaboration 
Handbook.31,32
RESULTS
Three papers were selected, which each reported on a single ran-
domized clinical trial that met the selection criteria.16,33,34 The same pa-
pers were found in more than one database as well as in the manual 
search. No randomized clinical trials that evaluated the effectiveness of 
lapatinib as monotherapy for first-line or second-line treatment of ad-
vanced or metastasized breast cancer were found. Nor were any random-
ized clinical trials assessing the effectiveness of lapatinib in association 
with another drug for first-line treatment for metastasized breast cancer 
found. The search strategy and its results are contained in Table 1.
The clinical trial included in the systematic review evaluated 324 
women with advanced breast cancer with HER-2 receptors (T4 prima-
ry tumor and stage IIIB or IIIC) or with metastasized cancer that had 
progressed subsequent to first-line treatment with anthracycline, taxane 
and trastuzumab.16 The cancer was evaluated according to the Response 
Evaluation Criteria in Solid Tumors (RECIST), modified to include le-
Table 1. Search strategies and results
Source Search strategy Number RCT criteria selection
Cochrane Library (lapatinib or tykerb or gw572016 or gw282974x or lapatinib and ditosylate) 16 1 
PubMed #1 (“lapatinib “[Substance Name]) OR (lapatinib) OR (GW 282974X) OR (GW-282974X) OR (GW282974X) OR 
(GW572016) OR (GW 572016) OR (GW-572016) OR (lapatinib ditosylate) OR (N-(3-chloro-4-(((3-fluorobenzyl)oxy)
phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine) OR (Tykerb)
#2 (“Breast Neoplasms”[Mesh]) OR (Breast Neoplasm*) OR (Neoplasm, Breast) OR (Breast Tumors) OR (Breast Tumor) OR 
(Tumor, Breast) OR (Neoplasms, Breast) OR (Tumors, Breast) OR (Breast Cancer) OR (Cancer, Breast) OR (Cancer of Breast) 
OR (Cancer of the Breast) OR (Mammary Carcinoma, Human) OR (Carcinoma, Human Mammary) OR (Carcinomas, Human 
Mammary) OR (Human Mammary Carcinomas) OR (Mammary Carcinomas, Human) OR (Human Mammary Carcinoma) 
OR (Mammary Neoplasms, Human) OR (Human Mammary Neoplasm) OR (Human Mammary Neoplasms) OR (Neoplasm, 
Human Mammary) OR (Neoplasms, Human Mammary) OR (Mammary Neoplasm, Human)
#3 (#1) AND (#2)
157 1
EMBASE Search: ‘lapatinib’/exp AND ‘breast cancer’/exp AND [embase]/lim. Mapped terms: ‘lapatinib’ mapped to ‘lapatinib’ , term 
is exploded
‘breast cancer’ mapped to ‘breast cancer’, term is exploded
Limited to: embase
Period: All Publication Years
424 1
Lilacs (“lapatinib “[Substance Name]) OR (lapatinib) OR (GW 282974X) OR (GW-282974X) OR (GW282974X) OR (GW572016) 
OR (GW 572016) OR (GW-572016) OR (lapatinib ditosylate) OR (N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-
methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine) OR (Tykerb) [Palavras]
0 0
SCIRUS ((lapatinib) OR (GW572016) OR (GW 572016) OR (Tykerb)) AND (breast neoplasm) 23 1 
Web of Science #1 TS=(lapatinib) DocType=All document types; Language=All languages; Database=SCI-EXPANDED; Timespan=1945-2007
#2 TS=(tyberk) DocType=All document types; Language=All languages; Database=SCI-EXPANDED; Timespan=1945-2007
#3 TS=tykerb DocType=All document types; Language=All languages; Database=SCI-EXPANDED; Timespan=1945-2007
#4 TS=lapatinib ditosylate DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 
Timespan=1945-2007
#5 TS=GW 572016 DocType=All document types; Language=All languages; Database=SCI-EXPANDED; Timespan=1945-
2007
#6 TS=breast Neoplasm DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 
Timespan=1945-2007
#7#5 OR #4 OR #3 OR #1DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 
Timespan=1945-2007
#8 #7 AND #6DocType=All document types; Language=All languages; Database=SCI-EXPANDED; Timespan=1945-2007
2 0
Manual Search -- 67 3
Total 689 7*
* There were overlaps in the references, resulting in a total of three papers, which actually reported the data from the same clinical study. Of these papers, one was an original article, and the others were congress abstracts pub-
lished in journal supplements. RCT = randomized clinical trial.
sions measuring 15 to 19 mm, with the ventricular ejection fraction 
within normal range as established by the institution and with the renal, 
hepatic and hematological systems functioning properly. Women with 
previous heart conditions, illnesses that could interrupt gastrointestinal 
absorption and patients who had ever received capecitabine as mono-
therapy before the beginning of this study were excluded. One group 
(n = 161) received capecitabine 2500 mg/m2/day orally on days 1 and 
14 in a 21-day cycle and the other group (n = 163) received capecitabine 
2000 mg/m2/day orally on days 1 and 14 every 3 weeks and lapatinib 
1250 mg/day orally, continuously. The randomization was implement-
ed in groups of six patients and, for the groups to be homogenous and 
comparable, they were stratified according to the cancer stage and the 
presence or absence of visceral disease. 
The primary outcome was the “progression time”, defined as the 
length of time between randomization and the occurrence of disease 
progression or death due to breast cancer. The secondary outcomes were: 
length of survival free from disease progression (the length of time be-
tween randomization and disease progression or death from any cause), 
the total response rate, the clinical benefit rate (full or partial response 
or stabilization of the disease for at least six months) and safety. The pa-
tients were evaluated every six weeks over the first 24 weeks and, subse-
quently, every 12 weeks over the duration of the treatment. Intention to 
treat (effectiveness) analysis was carried out.
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study as having moderate risk of bias.31,32 According to the level-of-ev-
idence classification established by the Oxford Centre for Evidence-
Based Medicine, the results from this clinical study support the use of 
lapatinib in association with capecitabine, at the doses prescribed and 
for this specific group of patients with advanced or metastasized breast 
cancer, with a level of evidence of 1b and a grade of recommendation of 
A.35 The study was financed and conducted by GlaxoSmithKline.
The published results from this trial correspond to an internal anal-
ysis (n = 324) on a study that intended to include 528 patients (statis-
tical power = 90%, α = 0.05) and which was conducted after 114 in-
stances of cancer progression. Since this analysis demonstrated that the 
addition of lapatinib to capecitabine was associated with a reduction in 
the risk of disease progression by 51%, the safety monitoring committee 
recommended that the study should be closed and that a report contain-
ing this information should be drafted. 
Based on updated data from this study, in March 2007 the Swiss 
government and the United States (US) Food and Drug Administration 
(FDA) approved the use of lapatinib in combination with capecitabine 
for treatment of metastasized or advanced breast cancer with HER-2 re-
ceptors, for patients who had received anthracycline, taxane and trastu-
zumab as first-line treatment.30,36 The updated results demonstrated that 
there was a significant increase in the average length of time until cancer 
progression in the combined-treatment group, from 18.6 to 27.1 weeks 
(HR = 0.57; 95% CI 95%: 0.43-0.77; P = 0.00013).36 The total re-
sponse rate also remained high in the combined-treatment group: 24% 
(95% CI: 18%-30.3%) versus 14% (95% CI: 9.5%-19.5%).36
No randomized clinical trials evaluating the effectiveness of lapa-
tinib in any of the following situations were found: a) as the sole first-
line or second-line treatment for advanced or metastasized breast can-
cer; b) as part of a combined treatment for the first-line or second-
line treatment of advanced or metastasized breast cancer; c) as part of a 
combined treatment for first-line treatment of advanced or metastasized 
breast cancer; or d) as part of a combined treatment with a drug other 
than capecitabine for second-line treatment of advanced or metastasized 
breast cancer. Therefore, Table 3 includes data from phase II and III 
clinical studies that have already been implemented or are in progress, 
with objectives that fit within the foregoing list.37-53
CONCLUSIONS
The combination of lapatinib and capecitabine was more effective 
than capecitabine alone for reducing the risk of cancer progression in 
Table 2. Outcomes from intention-to-treat (effectiveness) analysis16
Outcomes Lapatinib + capecitabine 
(n=163)
Capecitabine  alone 
(n=161) 
Risk ratio
(95% CI)
P-value
Average length of time until disease progression (months) 8.4 4.4 0.49 (0.34-0.71) < 0.001*
Average length of survival free from disease progression (months) 8.4 4.1 0.47 (0.33-0.67) < 0.001*
Total response rate % (95% CI) 22 (16-29) 14 (9-21) - 0.09†
Full response n (%) 1 (<1) 0 (0) - -
Partial response n (%) 35 (21) 23 (14) - -
Patients with clinical benefit n (%) 44 (27) 29 (18) - -
Deaths n (%) 36 (22) 35 (22) - -
CI = confidence interval. *log-rank test; † Fisher’s exact test.
Compared with capecitabine alone, the association of lapatinib and 
capecitabine doubled the average length of time until disease progression, 
which was 8.4 months for the latter and 4.4 months for the group treat-
ed solely with capecitabine (hazard ratio = 0.49; 95% confidence inter-
val, CI: 0.34-0.71; P < 0.001). In other words, the combined treatment 
reduced the risk of breast cancer progression by 50%, in relation to treat-
ment solely with capecitabine. An increase in the length of time until dis-
ease progression was observed for all patients in the group that received 
the combined treatment. The secondary outcomes are shown in Table 2.
Four patients in the combined therapy group developed cerebral 
metastasis as the first progression site, compared with 11 patients in the 
group treated solely with capecitabine (P = 0.10). The frequency of ad-
verse effects was similar in the two groups, with the exception of diar-
rhea, which occurred more frequently in the combined-treatment group 
(P < 0.001). The treatment discontinuation rate due to side effects was 
13% in the combined-therapy group and 12% in the group treated sole-
ly with capecitabine. The most common adverse effects in both groups 
were diarrhea, hand-foot syndrome, nausea, vomiting, fatigue and rash. 
Asymptomatic reduction of the left ventricular ejection fraction ≥ 20% 
was observed in four patients in the combined-treatment group and in 
one patient in the single-treatment group, but there were no symptom-
atic cardiac events or cases of discontinuation of the treatment due pri-
marily to cardiac function. 
DISCUSSION
Considering that only one clinical trial evaluating the effective-
ness of lapatinib for treating advanced or metastasized breast cancer 
was found and selected, and considering that this study only dealt with 
the use of lapatinib for second-line treatment and in association with 
capecitabine, there are limitations on the results from this systematic re-
view, despite their relevance. 
With regard to methodological evaluation, the study that was re-
viewed was given a rating of B on the scale set out in the Cochrane 
Collaboration Handbook and a rating of 3 on the Jadad scale, since it 
demonstrated an adequate randomization technique, was double blind 
and described losses and exclusions.31,32 Nevertheless, the study present-
ed a risk of breakage of the allocation concealment, since the method 
through which the treatments were administered was not considered 
identical between the two groups. This was because of a lack of report-
ing on whether the group treated solely with capecitabine also continu-
ously received placebo. The foregoing results allowed us to classify the 
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Table 3. Phase II and III studies on lapatinib for treatment of advanced or metastasized cancer
Study Intervention Phase Primary outcome Full response (%) Partial response (%) Stabilized disease (%) IPT (months)
First-line treatment
EGF2000937 lapatinib
1 dose/day versus 
2 doses/day
II GRR 0 35 35 NR
EGF3000138 paclitaxel/lapatinib versus 
paclitaxel/placebo
III IPT, GRR survival 
biomarker
In progress
EGF10438339 paclitaxel/trastuzumab/
lapatinib versus paclitaxel/
trastuzumab/placebo
III IPT, GRR survival 
biomarker
in progress
EGF3000840 letrozole/lapatinib versus 
letrozole/placebo
III IPT, GRR survival
biomarker
in progress
EGF10435341 paclitaxel/lapatinib versus 
paclitaxel/placebo
III IPT, GRR survival
biomarker
in progress
(Refractory) second-line or third-line treatment
EGF2000242,43 Lapatinib II GRR safety 8* - 14 22%†
EGF2000843,44 Lapatinib II GRR safety
cohort A (HER-2 +) 4* - 9+ 13%†
cohort B (HER-2 -) 0* - 1
EGF10490045 trastuzumab/lapatinib versus 
lapatinib
III GRR
SFP
in progress
EGF10508446 lapatinib (cerebral metastasis) II GRR 16.3% of the patients show a 20% volume reduction in the cerebral lesion 
NCI-CTEP 6969 47 lapatinib (cerebral metastasis) II GRR in the CNS 0 5‡ NR 3.2
Inflammatory breast cancer
EGF10390048 Lapatinib II GRR NR
cohort A 0 62 21
cohort B 0 8 17
EGF10258049 Lapatinib + paclitaxel versus 
(neoadjuvant)
II NR in progress
Adjuvant treatment
ALTTO50 trastuzumab one year versus
lapatinib one year versus
trastuzumab/lapatinib one year 
versus trastuzumab
three months →lapatinib nine 
months
III survival
IPT, GRR
safety
in progress
TEACH51,52 lapatinib one year versus 
placebo
III survival
SFI, QOL
recurrence CNS
in progress
Neoadjuvant treatment
NeoALTTO53 lapatinib/paclitaxel versus 
trastuzumab/paclitaxel versus 
lapatinib/trastuzumab/
paclitaxel
III GRR, IPT
safety
tolerability
survival
in progress
ALTTO = Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization; NeoALTTO = Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization; NR = not reported; QOL = quality of life; SFI = survival free from illness; SFP = 
survival free from progression; CNS = central nervous system; TEACH = Tykerb Evaluation After Chemotherapy; IPT = illness progression time; GRR = general response rate; EGF = epidermal growth factor.
* general response, including full and partial response; † 16 weeks of survival free from cancer progression; ‡CNS response/cerebral metastases response.
women with metastasized or advanced breast cancer with overexpres-
sion of HER-2 receptors and who had received first-line treatment with 
anthracycline, taxane and trastuzumab.
Lapatinib seems to be an adequate adjuvant treatment for HER-2-
positive breast cancer, since it demonstrates effectiveness in cases of ad-
vanced and metastasized cancer, appears to have few serious side effects 
and may be associated with reduction of the incidence of cerebral metas-
tasis, in addition to its easy oral administration once a day.
Randomized clinical trials need to be implemented, with the objec-
tive of assessing the effectiveness of lapatinib as monotherapy for first-
line or second-line treatment of advanced breast cancer, as well the ef-
fectiveness of lapatinib in associations as the primary treatment. An eco-
nomic study with a cost effectiveness evaluation is also necessary, in or-
der to incorporate this new technology into clinical practice.
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